This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Click here for Nimenrix® (meningococcal groups A, C, W-135 and Y conjugate vaccine) Prescribing Information.  Adverse event reporting information can be found at the bottom of the page.

Nimenrix in the Routine Immunisation Programme

Nimenrix (meningococcal groups A, C, W-135 and Y conjugate vaccine) is indicated for active immunisation of individuals from the age of 6 weeks against invasive meningococcal disease caused by Neisseria meningitidis groups A, C, W-135 and Y.1

Invasive meningococcal disease (IMD) is primarily associated with meningitis and septicaemia which can be fatal or have long-term consequences, even with appropriate medical care.2,3 

Up to 10% of patients who contract invasive meningococcal disease die.4

Up to 20% of survivors suffer severe long-term consequences5

Long-term consequences may include:2

Limb Amputation

Skin Scarring

Vision or Hearing Impairment

Mental or Motor Skill Impairment

Impaired Quality of Life

Certain behaviours in specific age groups are associated with an increased risk of invasive meningococcal disease:

  • Adolescents and young adults have the highest asymptomatic carriage rates, with almost 25% of 19-year-olds carrying the bacteria at any one time.6,7 
  • Social behaviours associated with an increased risk of invasive meningococcal disease in adolescents and young adults include:3,5,6,13



Mass Gatherings (eg sporting events or music festivals)

Close Living Quarters

Nimenrix is recommended in the routine immunisation schedule and is offered to teenagers aged 13-15 years old in school years 9 and 10.8,9
Some young adults today may not have received a MenACWY vaccination for which they are eligible.

If your patients were born on or after 1 September 1996 and are eligible but missed their teenage MenACWY vaccine, they can still have the vaccine up to their 25th birthday. If they are starting university for the first time, they can still have the vaccine up to their 25th birthday.9,10

These 3 simple steps can help protect your patients who are still eligible to receive a MenACWY vaccine:

1 Ask

Find out about your patient’s vaccination history:
“You may have missed out on the MenACWY vaccination programme. Have you had your MenACWY vaccine?”
If attempts to establish whether or not MenACWY vaccine has been administered are unsuccessful, individuals should be assumed to be unimmunised and MenACWY vaccination should be offered to those eligible to receive it.​​​​​​​11

2 Advice

Advise of the risks, especially for young adults:
“Young people are at higher risk of contracting invasive meningococcal disease compared to some other age groups.”12

3 Act

Help protect adolescents and young adults against invasive meningococcal disease caused by serogroups A,C,W and Y with a single dose of Nimenrix.1

Nimenrix is also recommended for patients with specific medical conditions, these include those with:8

  • asplenia or splenic dysfunction (including due to sickle cell and coeliac disease)
  • complement disorders (including those receiving complement inhibitor therapy)

Visit chapter 22 of the Green Book for more information

Go to the Green Book

For the routine immunisation programme Nimenrix should be ordered via IMMFORM


  1. Nimenrix. Summary of Product Characteristics, United Kingdom: Pfizer Ltd. Available here
  2. Vyse A, Anonychuk A, Jakel A, et al. The burden and impact of severe and long-term sequelae of Meningococcal disease. Expert Rev Anti Infect Ther. 2013;11(6):597–604.
  3. World Health Organization. Meningococcal meningitis, fact sheet. Available here  (last accessed March 2021).
  4. Chang Q, Tzeng Y, Stephens D. Meningococcal disease: changes in epidemiology and prevention. Clinical Epidemiology. 2012;4 237–245.
  5. Martinón-Torres F. Deciphering the burden of Meningococcal disease: conventional and under-recognized elements. J Adolesc Health. 2016;59 (2 suppl):S12–S20.
  6. Vetter V, Baxter R, Denizer G, et al. Routinely vaccinating adolescents against meningococcus: targeting transmission and disease. Expert Rev Vaccines 2016;15(5):641–58.
  7. Christensen H, May M, Bowen L, et al. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10(12):853–61.
  8. Public Health England. Complete routine immunisation schedule. Available here  (last accessed March 2021).
  9. NHS. Vaccinations: MenACWY Vaccines. Available here (last accessed March 2021).
  10. Public Health England. Vaccine Update, Issue 293, April 2019. Available here (last accessed March 2021).
  11. Public Health England. Vaccination of individuals with uncertain or incomplete immunisation status. Available here (last accessed March 2021).
  12. European Centre for Disease Prevention and Control. Factsheet about Meningococcal disease. Available here (last accessed March 2021).
  13. Muttalif A, Presa, J, Haridy, H et al. Incidence and Prevention of Invasive Meningococcal Disease in Global Mass Gathering Events. Infect Dis Ther. 2019;8:569–579.
PP-NIM-GBR-0248. March 2021

Ask Pfizer

Contact our Pfizer Vaccines UK team 

Contact Us

Visit our patient websites page for information about our patient support websites

Visit now

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020